@article{ATM22018,
author = {Laura C. Kennedy and Vijayakrishna Gadi},
title = {Dasatinib in breast cancer: Src-ing for response in all the wrong kinases},
journal = {Annals of Translational Medicine},
volume = {6},
number = {Suppl 1},
year = {2018},
keywords = {},
abstract = {Src is a non-receptor tyrosine kinase that has been associated with carcinogenesis, impairs osteoclast bone resorption, enhances angiogenesis in vivo, and plays a role in the development of breast cancer bone metastases (1-3). Writing in Clinical Breast Cancer, Morris et al. present the results of a single-arm phase II clinical trial evaluating a combination of paclitaxel and dasatinib, a Src inhibitor, in patients with HER2-negative metastatic breast cancer (4).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/22018}
}